Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$1.83
-2.1%		$2.10
$1.09
▼
$2.76
$204.34M0.621.54 million shs1.48 million shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$2.49
-0.8%		$2.80
$1.66
▼
$3.94
$382.41M22.23 million shs1.07 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
-5.08%-0.53%-3.11%+25.50%-41.74%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-2.71%+10.57%-11.31%-8.06%-35.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$1.83
-2.1%		$2.10
$1.09
▼
$2.76
$204.34M0.621.54 million shs1.48 million shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$2.49
-0.8%		$2.80
$1.66
▼
$3.94
$382.41M22.23 million shs1.07 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
-5.08%-0.53%-3.11%+25.50%-41.74%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-2.71%+10.57%-11.31%-8.06%-35.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alector, Inc. stock logo
ALEC
Alector
2.17
Hold$4.63152.73% Upside
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.71
Moderate Buy$5.83134.27% Upside

Current Analyst Ratings Breakdown

Latest EDIT and ALEC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/14/2026
Alector, Inc. stock logo
ALEC
Alector
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$5.00 ➝ $8.00
10/8/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeEqual Weight ➝ Overweight$4.00 ➝ $6.00
10/6/2026
Alector, Inc. stock logo
ALEC
Alector
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetUnderweight$2.00 ➝ $3.00
10/6/2026
Alector, Inc. stock logo
ALEC
Alector
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingNeutral$1.50
9/23/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeNeutral ➝ Buy$5.00
8/18/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
LADENBURG THALM/SH SH logo
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$6.00
8/13/2026
Alector, Inc. stock logo
ALEC
Alector
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
8/11/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
7/31/2026
Alector, Inc. stock logo
ALEC
Alector
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alector, Inc. stock logo
ALEC
Alector
$21.05M9.71N/AN/A$0.28 per share6.54
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$40.52M9.44N/AN/A$0.28 per share8.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alector, Inc. stock logo
ALEC
Alector
-$142.93M-$1.10N/AN/AN/A-850.13%-531.03%-44.00%11/5/2026 (Estimated)
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$160.06M-$0.75N/AN/AN/A-157.32%-196.63%-38.17%11/9/2026 (Estimated)

Latest EDIT and ALEC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.21N/AN/AN/A$4.54 millionN/A
11/5/2026Q3 2026
Alector, Inc. stock logo
ALEC
Alector
-$0.23N/AN/AN/A$2.38 millionN/A
8/6/2026Q2 2026
Alector, Inc. stock logo
ALEC
Alector
-$0.2286-$0.21+$0.0186-$0.21$1.71 million$3.32 million
8/5/2026Q2 2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.2705-$0.15+$0.1205-$0.15$2.85 million$11.89 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alector, Inc. stock logo
ALEC
Alector
N/AN/AN/AN/AN/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alector, Inc. stock logo
ALEC
Alector
0.80
5.26
5.26
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/A
3.19
3.19

Institutional Ownership

CompanyInstitutional Ownership
Alector, Inc. stock logo
ALEC
Alector
85.83%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
71.90%

Insider Ownership

CompanyInsider Ownership
Alector, Inc. stock logo
ALEC
Alector
8.30%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alector, Inc. stock logo
ALEC
Alector
103111.66 million102.39 millionOptionable
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
87153.58 million148.82 millionOptionable

Recent News About These Companies

Editas Medicine (NASDAQ:EDIT) Stock Price Breaks Below 50-Day Moving Average - What's Next?
October 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31128506
Editas Medicine (NASDAQ:EDIT) Stock Breaks Below 50 Day Moving Average - Here's Why
October 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-editas-medicine-nasdaq-edit-stock-breaks-below-50-day-moving-average-heres-why-2026-10-17/
Editas Medicine stock has November 9, 2026 earnings date
October 15, 2026  |  ad-hoc-news.deA
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
October 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/editas-medicine-announces-poster-presentations-130000456.html
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
October 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3380791/0/en/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference.html
Editas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic Shift
October 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4953511-editas-downgrade-hold-reni-cel-discontinuation-scdtdt-and-edit-401-strategic-shift
Editas Medicine (NASDAQ: EDIT) clears EDIT-401 for first-in-human trial in Australia
October 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31107406
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/edit-set-begin-first-human-145300858.html
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
October 9, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3003926/edit-set-to-begin-first-in-human-study-in-hypercholesterolemia?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-3003926
Editas Medicine Receives Approval To Initiate Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In Australia
October 9, 2026  |  marketscreener.comM
Wells Fargo Upgrades Editas Medicine to Overweight From Equal Weight, $6 Price Target
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/wells-fargo-upgrades-editas-medicine-151423083.html
Wells Fargo upgrades Editas Medicine to overweight from equal-weight
October 8, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/wells-fargo-upgrades-editas-medicine-to-overweight-from-equal-weight/ar-AA2dQK3Y
Editas Advances Gene-Editing Program Into First Human Study For High Cholesterol
October 8, 2026  |  rttnews.comhttps://www.rttnews.com/3697556/editas-advances-gene-editing-program-into-first-human-study-for-high-cholesterol.aspx
Editas Medicine stock gained 2.75 percent on October 7, 2026
October 8, 2026  |  ad-hoc-news.deA
Editas Medicine Receives Approval in Australia for Phase 3 Trial of EDIT-401 to Treat Hyperlipidemia
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/editas-medicine-receives-approval-australia-112827761.html
Editas upgraded at Wells Fargo as Australia approves gene editing trial
October 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4651469-editas-wins-australia-nod-gene-editing-trial
Editas Medicine clears first-in-human trial of EDIT-401 in Australia
October 8, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Editas+Medicine+clears+first-in-human+trial+of+EDIT-401+in+Australia/27163454.html
Update: Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/editas-medicine-shares-rise-australia-182552099.html
Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027
October 8, 2026  |  stocktwits.comS
Editas Medicine (NASDAQ:EDIT) Raised to Overweight at Wells Fargo & Company
October 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-editas-medicine-nasdaq-edit-raised-to-overweight-at-wells-fargo-company-2026-10-08/
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/editas-medicine-receives-approval-initiate-110000549.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alector stock logo

Alector NASDAQ:ALEC

$1.83 -0.04 (-2.14%)
Closing price 04:00 PM Eastern
Extended Trading
$1.79 -0.04 (-2.40%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Editas Medicine stock logo

Editas Medicine NASDAQ:EDIT

$2.49 -0.02 (-0.80%)
Closing price 04:00 PM Eastern
Extended Trading
$2.48 -0.01 (-0.20%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas